8-K: NeuroPace Reports Record Quarterly Revenue and Raises Full-Year Guidance

NeuroPace announced record quarterly revenue of $22.5 million for Q1 2025 and increased its full-year revenue guidance to $93-$97 million.

Summary

• NeuroPace reported a 24% year-over-year increase in revenue, reaching $22.5 million in the first quarter of 2025.
• RNS System revenue grew by 26% year-over-year, or 29% excluding NAUTILUS study implants from Q1 2024.
• The company achieved a strong gross margin of 77.0% in Q1 2025, exceeding its full-year guidance range.
• Operating expenses increased by 8% year-over-year, demonstrating operating leverage.
• NeuroPace is strategically refocusing on its core RNS System and will terminate its SEEG product distribution relationship between Q4 2025 and Q1 2026.
• Full-year 2025 revenue guidance has been increased to $93-$97 million, representing a 16%-21% growth compared to 2024.
• The company's cash, cash equivalents, and short-term investments totaled $66.3 million as of March 31, 2025.
• Long-term borrowings totaled $59.8 million as of March 31, 2025.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with record revenue, increased guidance, and strong gross margins. While there is a net loss, the overall tone is optimistic due to growth and strategic refocusing.

Positives

• Record quarterly revenue of $22.5 million indicates strong market demand.
• Increased full-year revenue guidance to $93-$97 million reflects confidence in continued growth.
• Strong gross margin of 77.0% demonstrates efficient cost management.
• Operating leverage is improving, with operating expenses growing at a slower rate than revenue.
• Positive data from the Post-Approval Study of the RNS System supports its efficacy.

Negatives

• The company experienced a net loss of $6.6 million for the first quarter of 2025.
• The company is terminating its distribution relationship for SEEG products, which will begin winding down in the fourth quarter of 2025 and continue through the first quarter of 2026.

Risks

• The company's future performance is subject to various risks, including market acceptance of the RNS System, regulatory approvals, and product development challenges.
• Reliance on third-party contractors and single-source suppliers could pose risks to the supply chain.
• The company's long-term debt totals $59.8 million as of March 31, 2025.

Future Outlook

NeuroPace has increased its full-year 2025 revenue guidance to $93-$97 million, representing a 16%-21% growth compared to 2024. The company anticipates expanding into new patient populations and launching differentiated software products.

Management Comments

• 'We are encouraged by the continued strength of our commercial execution to start 2025, with revenue growth driven by an expanding base of prescribing physicians and increasing traction from our Project CARE initiative,' said Joel Becker, Chief Executive Officer of NeuroPace.
• Management remains focused on increasing access to RNS therapy, delivering operating leverage, advancing product development, and positioning the Company for sustained revenue growth and long-term value creation.

Industry Context

NeuroPace's focus on the RNS System aligns with the growing trend of personalized medicine and targeted therapies in the medical device industry. The company's strategic refocusing on its core product line suggests a move towards greater efficiency and market penetration in the epilepsy treatment space.

Comparison to Industry Standards

• Comparing NeuroPace's 24% revenue growth to other medical device companies in the neuromodulation space, such as Medtronic or Boston Scientific, provides context on its market performance.
• The 77% gross margin is strong compared to typical medical device margins, suggesting efficient operations and pricing strategies.
• The company's focus on AI-powered software aligns with industry trends towards incorporating advanced technology into medical devices.

Stakeholder Impact

• Shareholders can expect potential long-term value creation through sustained revenue growth.
• Patients with drug-resistant epilepsy may benefit from increased access to RNS therapy.
• Employees may experience changes due to the strategic refocusing and termination of the SEEG product distribution relationship.

Next Steps

• NeuroPace will announce topline data from the NAUTILUS pivotal study in the second half of 2025.
• The company will continue winding down its distribution relationship for SEEG products between Q4 2025 and Q1 2026.
• The company will focus on expanding into new patient populations and launching differentiated software products.

Key Dates

Keywords

NeuroPace, RNS System, epilepsy, revenue, financial results, medical device